NEW YORK (GenomeWeb News) – Florida has licensed Provista Diagnostics to offer clinical laboratory services for patient samples originating within the state, the company said today.
The Scottsdale, Ariz.-based molecular diagnostic firm received the Out of State Laboratory License from the Clinical Laboratory Unit of the Florida Agency for Healthcare Administration. As a result, Provista can now offer its clinical lab services to 49 of the 50 states in the US, with New York being the exception.
The company said that it plans to apply to New York for licensure, as well as for increased lab accreditation from the College of American Pathologists.
Provista's lab services are offered through its CLIA-certified PDx Reference Laboratory. Services that are provided include testing services such as consultation, assay evaluation and development, method development, clinical laboratory services, clinical trial design and diagnostic support, analytical regulatory guidance, and companion diagnostics.
Provista is a molecular diagnostic firm developing diagnostics, prognostics, and predictive tests for cancers affecting primarily women, including breast, endometrial, and ovarian cancers. It also provides diagnostic testing and clinical laboratory services to pharmaceutical and biotech companies through its PDx Reference Laboratory.
Last month, it announced it pulled in $6 million in a Series A preferred financing round.